Corvus Pharmaceuticals, Inc. — Director's Dealing 2020

Mar 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2020-03-19

Reporting Person: Grais Linda S (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-19	Stock Option (Right to Buy)	$2.00	A	15000	Acquired	2030-03-19	Common Stock (15000)	Direct

Footnotes

F1: 100% of the shares subject to the option vest and become exercisable on the one-year anniversary of the grant date, subject to continued service as a director through such date.